within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AX05_Pirfenidone;

model Pirfenidone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.81,
    Cl = 4.083333333333333e-06,
    adminDuration = 600,
    adminMass = 801 / 1000000,
    adminCount = 1,
    Vd = 0.0592,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.01115,
    Tlag = 17.4);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Pirfenidone</td></tr><tr><td>ATC code:</td><td>L04AX05</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>801</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>59.2</td><td>L</td></tr>
    <tr><td>clearance:</td><td>14.7</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Pirfenidone is an orally administered antifibrotic agent used for the treatment of idiopathic pulmonary fibrosis (IPF). It exhibits antifibrotic, anti-inflammatory, and antioxidant properties. Pirfenidone is approved for clinical use in the treatment of IPF in multiple countries including the US, EU, and Japan.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects (male and female, aged 18–55 years) after single-dose administration.</p><h4>References</h4><ol><li><p>Rastegar-Pouyani, N, et al., &amp; Sahebkar, A (2024). Targeting cancer-associated fibroblasts with pirfenidone: A novel approach for cancer therapy. <i>Tissue &amp; cell</i> 91 102624–None. DOI:<a href=\"https://doi.org/10.1016/j.tice.2024.102624\">10.1016/j.tice.2024.102624</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39581071/\">https://pubmed.ncbi.nlm.nih.gov/39581071</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L04AX05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Pirfenidone;
